The FDA told the San-Francisco based biotech to halt the PALIZADE study (NCT05781750), a Phase IIb trial investigating ...
The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...
Investment analysts at William Blair upped their FY2024 EPS estimates for Kezar Life Sciences in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Phipps now expects ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics ...
PALIZADE – Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis (LN) (ClinicalTrials.gov: NCT05781750) In October, Kezar made the strategic decision to terminate the ...
PALIZADE - Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis (LN) (ClinicalTrials.gov: NCT05781750) In October, Kezar made the strategic decision to terminate the ...
GlobalData on MSN5d
Kezar struck again with second FDA holdKezar’s CEO, Dr. Chris Kirk said: “We are working to understand the safety events that occurred in the PALIZADE trial in ...
“The team at Kezar has made great progress towards ... the safety events that occurred in the PALIZADE trial in lupus nephritis, including deaths that occurred in both the placebo and drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback